Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Retrieved on:
Thursday, August 12, 2021
Journal of Medicinal Chemistry, Forward-looking statement, CLL, Research, 8-K, Securities Act of 1933, Form 10-K, BTK, COVID-19, American Society of Clinical Oncology, GLOBE, R, Treatment, Failure, Journal, Drug Quality and Security Act, Patient, Ovarian cancer, P-TEFb, MYC, PALO, DLBCL, G&A, Securities Exchange Act of 1934, Aggressive lymphoma, CDK9, FIH, Nasdaq, Society, Therapy, ASCO, Fine chemical, Pharmaceutical industry, Risk management
PALO ALTO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Points:
- PALO ALTO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
- Our balance sheet provides us with a solid foundation to continue to execute on our clinical and regulatory goals.
- Net loss for the second quarter ended June 30, 2021 was $2.0 million, or $0.12 per share, basic and diluted.
- Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.